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Abstract: Calorie restriction (CR) is the most robust intervention that decreases morbidity and mortality, and thereby in-
creases the lifespan of many organisms. Although the signaling pathways involved in the beneficial effects of CR are not 
yet fully understood. Several candidate pathways and key molecules have been identified. The effects of CR are highly 
conserved from lower organisms such as yeast to higher mammals such as rodents and monkeys. Recent studies have also 
demonstrated beneficial effects of CR in humans, although we need much longer studies to evaluate whether CR also in-
creases the lifespan of humans. In reality, it is difficult for us to conduct CR interventions in humans because the subjects 
must be kept in a state of hunger and the duration of this state needed to achieve a clinically meaningful effect is still un-
known. Thus, research in this field is focusing on the development of molecules that mimic the beneficial effects of CR 
without reducing food intake. Some of these candidate molecules include plant-derived functional chemicals (phyto-
chemicals), synthetic small molecules, and endocrine molecules such as adipokines. Several studies have already shown 
that this research field may yield novel drugs for the treatment of age-related diseases such as diabetes. In this article, we 
describe the target pathways, candidate molecules, and strategies to develop CR mimetics. 
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1. INTRODUCTION  
  A moderate (30–40%) restriction of calorie intake, but 
not malnutrition, reduces morbidity and mortality in labora-
tory animals compared with animals given free food access 
[1]. It has been shown that the anti-aging effects of calorie 
restriction (CR) are due to restricted dietary calorie intake, 
rather than the restriction of specific nutrients [2]. Compared 
with many other attempts to manipulate the aging process in 
animal models, CR remains the most robust anti-aging inter-
vention studied to date [3]. Although, the critical signaling 
pathways underlying the anti-aging effects of CR have not 
been fully elucidated, it is thought that CR regulates the ag-
ing processes, in part, through its effects on the neural and/or 
endocrine regulatory systems [2]. In particular, neuropep-
tides and insulin/insulin-like growth factor-I (IGF-I) seem to 
be important molecular mediators of the adaptive metabolic 
response to CR [4-7]. In the neuroendocrine system, our pre-
vious study showed that the leptin–neuropeptide Y (NPY) 
pathway has important roles in the effects of CR [8, 9]. Be-
cause of the robustness of CR, many researchers have tried 
to identify the molecules that mimic the beneficial effects of 
CR as candidate drugs for age-related diseases [3, 10]. Some 
of these results suggest that this research field could be a 
promising approach to develop drugs for human diseases   
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such as obesity, diabetes, inflammatory and neurodegenera-
tive diseases [11]. 
2. EFFECTS OF CALORIE RESTRICTION IN HU-
MANS  
  A longitudinal epidemiological study has been conducted 
in Baltimore (ML, USA, Baltimore Longitudinal Study of 
Aging), and many interesting findings have reported. One of 
the most remarkable results among those studies is the find- 
ing of biomarkers of longevity in humans. The study showed 
that low body temperature, low blood insulin, and high de- 
hydroepiandrosterone sulfate were characteristics of human 
longevity [12]. Those changes were similar to those ob- 
served in CR rodents and monkeys. Although these are indi- 
rect findings, the results suggest that CR in humans might 
also have beneficial effects, as observed in laboratory ani- 
mals. On the other hand, several ongoing projects have sub- 
jected humans to CR directly. One of these studies, the 
CALERIE (Comprehensive Assessment of Long-term Ef- 
fects of Reducing Intake of Energy) project, has started in 
multiple institutions in the United States, and some positive 
effects on human health of 6 months of CR have already 
been reported [13]. However, the complexity of human ge- 
netics and the relatively short duration of these projects, as 
compared with the human lifespan, make it difficult to evalu- 
ate the long-term effects of CR on humans. Clearly, a life- 
long clinical study is needed to confirm the anti-aging effects 
of CR in humans, although this is unrealistic. Even if science 
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humans can reduce morbidity and mortality, and maintain 
function to the same degree as observed in experimental 
animals, questions remain as to whether to pursue CR in 
humans. First, we must be kept in hunger for a significant 
period of time during daily life. Second, we do not yet know 
how great and long the CR needs to be in humans to achieve 
clinically relevant effects. Third, CR in humans could have 
adverse effects such as infertility and osteoporosis. These 
obstacles have encouraged researchers to identify and de-
velop molecules that can mimic the anti-aging, pro-longevity 
effects of CR, without reducing caloric intake. 
3. CR MIMETICS  
  The concept of CR mimetics is relatively new [3]. It has 
been proposed that CR mimetics should have the following 
key features: (i) they should mimic the metabolic, hormonal 
and physiological effects of CR; (ii) they should not signifi-
cantly decrease long-term food intake; (iii) they should acti-
vate stress–response pathways, as observed in CR, and pro-
tect against a variety of stressors; and (iv) they should reduce 
inflammation and autoimmunity. Several studies have been 
conducted to evaluate whether existing drugs mimic these 
properties using microarray-based gene expression analysis 
in mice [14, 15]. The results of those studies suggest that the 
anti-diabetic drug metformin and peroxisome proliferator-
activated receptor  (PPAR) activators are potential candi-
date CR mimetics. The results also suggest that modulation 
of metabolism (including glucose and lipid metabolism) and 
inflammation could be major targets for the development of 
CR mimetics in terms of similar gene expression patterns. 
Therefore, CR mimetics could be used for the treatment of 
obesity, diabetes, and inflammatory diseases. 
3.1. Metformin  
  Metformin, one of the most widely used type 2 diabetes 
therapeutics, requires liver kinase B1 (LKB1) in the liver to 
reduce blood glucose levels [16]. LKB1 phosphorylates and 
activates AMPK [adenosine monophosphate (AMP)-
activated protein kinase]. Deletion of LKB1 in the liver of 
mice resulted in an almost complete loss of AMPK activity. 
Furthermore, the loss of LKB1 function resulted in hyper-
glycemia with increased gluconeogenic and lipogenic gene 
expression. We previously found that AMPK activity was 
decreased in the liver of CR rats [17]. We also found en-
hanced expression of gluconeogenic and lipogenic genes in 
the CR rat liver [8, 18]. These results suggest that, at least in 
the liver, AMPK activity should be downregulated to main-
tain glucose and lipid metabolism in CR rats. Even though 
metformin can activate AMPK, it is a potential CR mimetic 
[15]. Interestingly, their microarray study revealed that 8 
weeks of metformin treatment had more pronounced effects 
on CR-like gene expression than 8 weeks of CR. Thus, in the 
liver, metformin might optimize the activity or responses of 
the LKB1–AMPK pathway to maintain appropriate glucose 
and lipid metabolism, depending on the energy requirements. 
We also found that a novel insulin signaling molecule, WD-
repeat protein 6 (WDR6), interacts with LKB1 [19-21]. 
Therefore, this molecule might also be involved in the adap-
tation of glucose and lipid metabolism in CR, and is a puta-
tive target for the development of CR mimetics.  
  Metformin treatment in cancer-prone female human epi-
dermal growth factor receptor type 2 (HER-2)/neu transgenic 
mice induced a phenotype similar to that in CR mice, with 
suppression of the age-associated rise in blood glucose and 
lipid levels [22]. In that study, metformin significantly de-
creased the incidence and size of tumors, and increased the 
lifespan of mice [22]. However, metformin did not signifi-
cantly increase the lifespan of normal Fischer 344 rats com-
pared with control rats [23]. These results suggest that the 
CR-mimetic effects of metformin are species-specific or 
function only in disease-prone conditions. Nevertheless, 
these results suggest that modulation of the LKB1–AMPK 
signaling pathway could be an attractive target for the devel-
opment of CR mimetics.  
3.2. Adipokines 
  Adipokines, adipose tissue-derived hormonal factors, 
could be important mediators of the beneficial effects of CR 
[5]. We previously demonstrated that downregulation of 
leptin and resistin, and upregulation of adiponectin are char-
acteristics of CR animals [8, 24, 25]. Adiponectin is a posi-
tive regulator of the beneficial effects of CR and may be an 
important target for the development of CR mimetics. Ya-
mauchi et al. [26] showed that adiponectin has two different 
receptors, adiponectin receptors 1 and 2 (AdipoR1 and Adi-
poR2), which have important roles in the regulation of glu-
cose and lipid metabolism, inflammation and oxidative stress 
in vivo. In the liver, AdipoR1 activates the AMPK pathways 
and AdipoR2 activates PPAR pathways [26]. A recent 
study showed that AMPK controls the expression of genes 
involved in energy metabolism in mouse skeletal muscle by 
acting in coordination with SIRT1 (sirtuin 1) [27], an NAD
+-
dependent deacetylase [28]. AMPK enhances SIRT1 activity 
by increasing cellular NAD
+ levels, resulting in the deacety-
lation and modulation of the activity of downstream SIRT1 
targets such as PPAR coactivator 1 (PGC-1) and fork-
head box O1 (FoxO1). Moreover, this AMPK–SIRT1 path-
way in muscle is regulated by the adiponectin–adipoR1 sys-
tem [29]. Taken together with the finding that CR does not 
activate AMPK [17] or SIRT1 [30] in the liver, CR mediated 
upregulation of adiponectin might contribute to the regula-
tion of metabolism in muscle, but not in the liver. Therefore, 
development of CR mimetics that target the adiponectin–
AMPK pathway should be activated in a tissue-specific 
manner. 
3.3. NPY 
  We previously reported that NPY has important roles in 
the neuroendocrine adaptations of CR [8-9]. NPY was found 
to enhance the stress response and regulate the expression of 
adipokines [8]. Moreover, NPY transgenic rats showed an 
increased lifespan [31]. One of the major endogenous NPY 
activators is the gut-derived hormone ghrelin [32, 33]. In 
both rodents and humans, plasma ghrelin concentrations in-
crease during fasting to stimulate the feeding behavior. CR 
can suppress the growth hormone (GH)–IGF-I pathway, but 
ghrelin activates pituitary GH secretion via  its receptor, 
GHS-R. Therefore, during CR, the increased expression of 
ghrelin might selectively activate the NPY pathway but not 
GH secretion. Indeed, we found an inverse relationship be-
tween NPY and GH gene expression in CR rats [8]. It has 564    Current Genomics, 2010, Vol. 11, No. 8  Chiba et al. 
been shown that infusion of thyroid hormone [triiodothy-
ronine (T3)] activated the hypothalamic NPY–NPY-Y1 re-
ceptor pathway by reducing the circulating leptin level, but 
not by increasing the circulating ghrelin level [34]. There-
fore, leptin signaling might be more sensitive than ghrelin 
signaling to induce NPY expression in the hypothalamus. 
Interestingly, a recent study showed that SIRT1 regulates 
thyroid-stimulating hormone release from pituitary cells, 
which is involved in T3 secretion [35]. These results suggest 
that sirtuin activators might have potential effect as NPY 
activators by modulating T3 induction to reduce the leptin 
level and thereby increase NPY activity.  
3.4. Rapamycin 
  Inhibition of the target of rapamycin (TOR) signaling 
pathway by genetic or pharmacological intervention extends 
lifespan in yeast, nematodes and flies [36-40]. In these three 
organisms, CR is mediated, at least in part, by reduced TOR 
signaling [37, 38, 41, 42]. Moreover, mice fed with rapamy-
cin to inhibit the mTOR pathway showed significantly in-
creased lifespan compared with control mice [43]. They also 
evaluated the phosphorylation levels of ribosomal protein 
subunit S6 (rpS6), a target substrate of S6 kinase 1 (S6K) in 
the mTOR signaling pathway [44]. Rapamycin-fed mice 
showed a significant reduction in the levels of phosphory-
lated rpS6 compared with control mice in adipose tissue. 
Consistent with those findings, knockout of S6K increased 
the lifespan of mice [45]. Interestingly, sestrin was identified 
as a feedback inhibitor of TOR in flies [46]. Loss of sestrin 
resulted in age-associated pathologies including triglyceride 
accumulation, mitochondrial dysfunction, muscle degenera-
tion and cardiac malfunction, which were prevented by 
activation of AMPK or inhibition of TOR. These results 
indicate that the TOR pathway could be an important 
signaling pathway that regulates various biological functions 
implicated in aging [47]. Therefore, rapamycin and related 
molecules that inhibit the TOR pathway may be attractive 
candidate CR mimetics. 
3.5. Sirtuin Activators 
3.5.1. Resveratrol 
  Orthologs of mammalian SIRT1 (Sir2 in yeast, sir-2.1 in 
nematodes, dSir2 in flies) were shown to promote longevity 
in these species in some conditions [48]. Because CR did not 
extend the lifespan of SIRT1-deleted organisms, they con-
sidered that the beneficial effects of SIRT1 activation and 
CR involved similar pathways [48]. Howitz et al. [49] per-
formed a screening study to identify activators of human 
SIRT1 and reported several candidate molecules, which in-
cluded resveratrol. Resveratrol is a polyphenolic compound 
present in high amounts in red grapes and in wine [50]. Res-
veratrol has been shown to increase the lifespan of nema-
todes and fruit flies in a sirtuin-dependent manner, which 
appeared to mimic CR [51]. Furthermore, epidemiological 
studies have demonstrated that consumption of resveratrol 
could reduce the risk of many age-related diseases [52]. 
However, other reports have suggested that resveratrol does 
not have pro-longevity effects in yeast [53]. Moreover, the 
pro-longevity effects of resveratrol in nematodes and fruit 
flies were not observed in another study [54]. Meanwhile, 
one study showed that resveratrol inhibited SIR-2.1 activity 
in nematodes [55]. 
  On the other hand, in a study in mice, resveratrol shifted 
the physiology of middle-aged mice fed with a high-calorie 
diet towards that of control diet-fed mice, and significantly 
increased their lifespan [56]. Resveratrol induces various 
changes, as observed in CR mice, including increased insulin 
sensitivity, reduced IGF-I levels, and increased PGC-1 ac-
tivity [56]. In other studies, resveratrol was shown to influ-
ence gene expression in multiple tissues, with similar 
changes to those induced by CR. However, mice fed a stan-
dard diet did not live longer when they were treated with 
resveratrol starting at 12 months of age [50]. These results 
suggest that the CR-mimetic effects of resveratrol are more 
evident in disease states, such as obesity and diabetes in 
mice.  
3.5.2. Other Small Molecules 
 Milne  et al. [57] published results of their study in which 
they identified extremely strong SIRT1 activators from a 
small molecule library. One of the molecules, SRT1720, is 
structurally unrelated to, but was 1000-fold more potent than 
resveratrol for the activation of SIRT1 in their assay system. 
Using obese mice, they also showed that SRT1720 improved 
insulin sensitivity, lowered blood glucose, and increased 
mitochondrial capacity [57]. These results suggest that 
SIRT1 activators offer a promising new approach to treat 
age-related diseases such as diabetes, and this compound is 
currently being tested in clinical trials [57]. However, a more 
recent study demonstrated that resveratrol and SRT1720 do 
not directly activate SIRT1 [58]. In fact, they reported a po-
tential problem with the SIRT1 activator screening system 
used to identify resveratrol and SRT1720, as described be-
low. 
4. SCREENING OF CR MIMETICS 
 Pacholec  et al. [58] assessed the previously identified 
SIRT1 activators using biochemical assays with native sub-
strates, including a p53-derived peptide substrate without a 
fluorophore, as well as the purified native full-length protein 
substrate p53. They found that resveratrol and SRT1720 did 
not activate SIRT1 with the native peptide or full-length pro-
tein substrates. These compounds only activated SIRT1 with 
a peptide substrate containing a covalently attached fluoro-
phore, as observed in an earlier study that identified several 
SIRT1 activators [57]. Therefore, they concluded that res-
veratrol and SRT1720 are not direct activators of SIRT1. 
They also revealed that there are various off-targets of these 
sirtuin activators, which showed no beneficial effects in 
high-fat diet-fed mice. Howitz et al. [49] originally devel-
oped an in vitro screening system for CR mimetic sirtuin 
activators. However, it has already been reported that this 
screening system may be affected by the use of fluorophores 
[53]. It is possible that fluorophores might mimic an uniden-
tified protein function needed for in vivo activation of SIRT1 
by these compounds. In fact, the beneficial effects of these 
molecules have not reproduced in vivo [58]. Most recently, 
Dai  et al. [59] reported that some sirtuin activators could 
accelerate SIRT1-catalyzed deacetylation of unlabeled pep-
tides, and that the activators interact directly with SIRT1 and 
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However, they would need to show that their compounds 
enhance deacetylation of native p53 to confirm their conclu-
sions. Therefore, we believe that further studies are needed 
to resolve this controversy, although SIRT1 activation in 
specific tissues might offer a promising approach to develop 
CR mimetics. On the other hand, novel screening systems 
are needed to identify possible candidate CR mimetics.  
  The development of an effective screening system will 
greatly accelerate the identification of potential candidates 
and expand this research field. Screening processes can be 
based on cell systems or animal model systems, such as bio-
sensor mice using a secreted alkaline phosphatase reporter 
[60, 61]. To do this, we must identify the sequence of the 
cis-acting elements upstream of the potential pro-longevity 
genes. The accumulation of DNA microarray data would be 
helpful to achieve this goal. Such approaches have already 
been used to identify various regulatory systems in yeast, 
and have identified several sequence motifs, such as those 
that are important in the heat shock stress response [62]. 
Such strategies could be exploited to develop CR mimetic 
screening systems using the previously reported data [63]. 
We have developed such a screening system, which we have 
named as CRISP—the CR-Imitating agent Screening Plat-
form [64]. We have already demonstrated the effectiveness 
and specificity of this screening platform. Nevertheless, can-
didate CR mimetics must still be verified by showing that 
their beneficial effects are similar to those of CR. Such com-
pounds should function in healthy animals and in animal 
models of disease, without any deleterious effects. This stage 
of development would be the most time- and cost-consuming 
process. Moreover, large-scale collaboration is necessary to 
confirm the effects of candidate molecules, such as that con-
ducted in the assessment of rapamycin, which showed pro-
longevity effects in mice bred at different institutions [43].  
5. CONCLUSIONS 
  There are multiple in vivo targets involved in the effects 
of CR. Therefore, it is likely that there are other pathways 
that regulate aging and age-related disorders, to mediate the 
effects of CR, other than those discussed in this article. Ac-
cordingly, approaches involving a single molecule or a sin-
gle pathway might show limited effects as a CR mimetic. 
However, the development of CR mimetics may offer an 
elixir for healthy life of humans, and recent and ongoing 
studies are showing much promise to accomplish this goal. 
This field of research has attracted scientists from many dif-
ferent backgrounds, including neurobiologists, endocrinolo-
gists, nutritional scientists and biomedical gerontologists. 
Interdisciplinary and integrated collaboration of these disci-
plines would accelerate the research endeavors. 
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